Pathophysiology · MU Sofia

91. Erythrocytosis and polycythemia rubra vera - etiology, pathogenesis, clinical manifestations.

Inside: 1 section · 1 table · 15 flashcards · 2 min

Topic 91 of 168 in the MU Sofia syllabus for Pathophysiology (Medicine, Year 3). The free AceMed note covers it in 1 section, about 257 words (2 min of reading), with 15 flashcards.

In this note

  1. Erythrocytosis and polycythemia rubra vera – etiology, pathogenesis, and clinical manifestations

Erythrocytosis and polycythemia rubra vera – etiology, pathogenesis, and clinical manifestations

Erythrocytosis is an increase in red blood cell mass, resulting in elevated hemoglobin and hematocrit levels.

Etiology

  • Primary erythrocytosis
  • Polycythemia vera (see below).
  • Secondary erythrocytosis
  • Due to increased erythropoietin (EPO) production:
  • Chronic hypoxia:
  • High altitude.
  • Chronic obstructive pulmonary disease (COPD).
  • Cyanotic congenital heart disease.
  • Ectopic EPO production:
  • Renal cell carcinoma.
  • Hepatocellular carcinoma.
  • Cerebellar hemangioblastoma.
  • Relative erythrocytosis
  • Hemoconcentration due to plasma volume loss:
  • Severe dehydration.
  • Burns.

Pathogenesis

  • Increased EPO or RBC mass → increased blood viscosity → impaired microcirculation.
  • Risk of thrombosis and vascular complications.
  • Clinical manifestations
  • Ruddy (plethoric) complexion.
  • Headache, dizziness.
  • Visual disturbances.
  • Hypertension.
  • Thrombosis risk: stroke, myocardial infarction.
  • Pruritus (especially after hot bath — mostly in polycythemia vera).

Polycythemia rubra vera (polycythemia vera, PV)

A chronic myeloproliferative neoplasm characterized by clonal proliferation of erythroid precursors, leading to increased red cell mass, often also involving leukocytosis and thrombocytosis.

  • Etiology
  • Somatic mutation in JAK2 gene (JAK2 V617F mutation) in ~95% of cases.
  • Independent of erythropoietin levels (EPO levels typically low).
  • Pathogenesis
  1. JAK2 mutation → constitutive activation of JAK-STAT signaling → increased erythroid precursor proliferation in bone marrow.
  2. Increased RBC mass → hyperviscosity → sluggish blood flow and thrombosis.
  3. Possible progression to "spent phase" with bone marrow fibrosis or acute leukemia.

Clinical manifestations

  • General
  • Plethoric (red) face.
  • Cyanosis (due to slow-flowing, deoxygenated blood).
  • Neurological
  • Headache.
  • Dizziness.
  • Visual disturbances.
  • Tinnitus.
  • Vascular
  • Hypertension.
  • Thrombotic events: deep vein thrombosis, stroke, myocardial infarction.
  • Budd-Chiari syndrome (hepatic vein thrombosis).
  • Skin
  • Pruritus after warm bath or shower (aquagenic pruritus).
  • Gastrointestinal
  • Peptic ulcer disease (due to increased histamine release).
  • Splenomegaly
  • Due to extramedullary hematopoiesis.

Summary table

Read the full note free

The whole note is free with an AceMed account, with its 15 flashcards. Premium adds flashcard recall, highlights and Ask AI.